Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24220| Title: | Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 | Authors: | Rech, J. Reinhardt, M. Kavanaugh, A. GEUSENS, Piet Mpofu, S. |
Issue Date: | 2017 | Publisher: | WILEY | Source: | JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 15(S1), p. 141-141 (Art N° P138) | Notes: | [Rech, J.] Univ Erlangen Nurnberg, Dept Rheumatol & Immunol, Erlangen, Germany. [Reinhardt, M.] Novartis Pharma GmbH, Nurnberg, Germany. [Kavanaugh, A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Geusens, P.] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Mpofu, S.] Novartis Pharma AG, Basel, Switzerland. | Document URI: | http://hdl.handle.net/1942/24220 | ISSN: | 1610-0379 | e-ISSN: | 1610-0387 | ISI #: | 000400154800356 | Category: | M | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| annrheumdis.pdf Restricted Access | Published version | 150.17 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.